Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients

dc.creatorvon Glehn, F
dc.creatorFarias, AS
dc.creatorde Oliveira, ACP
dc.creatorDamasceno, A
dc.creatorLonghini, ALF
dc.creatorOliveira, EC
dc.creatorDamasceno, BP
dc.creatorSantos, LMB
dc.creatorBrandao, CO
dc.date2012
dc.dateJUL
dc.date2014-08-01T18:29:44Z
dc.date2015-11-26T18:05:00Z
dc.date2014-08-01T18:29:44Z
dc.date2015-11-26T18:05:00Z
dc.date.accessioned2018-03-29T00:47:14Z
dc.date.available2018-03-29T00:47:14Z
dc.identifierMultiple Sclerosis Journal. Sage Publications Ltd, v. 18, n. 7, n. 1038, n. 1041, 2012.
dc.identifier1352-4585
dc.identifierWOS:000305754800020
dc.identifier10.1177/1352458511428465
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/79695
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/79695
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1293009
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionIntrathecal immunoglobulin synthesis in an oligoclonal pattern is the most common immunologic abnormality detected in MS patients. Various treatments, such as immunomodulators and immunosuppressors, have not been found to modify it. Natalizumab hinders migration of encephalitogenic T-cells into the central nervous system (CNS), reducing inflammatory response. Its impact on CSF oligoclonal bands (OCBs) has not been demonstrated. This report describes its effect in four out of six patients with multiple sclerosis after a mean of 10 infusions: the CSF was negative for OCBs at the second lumbar puncture. In conclusion, natalizumab treatment can reduce CSF OCBs to undetectable levels, although the clinical significance of this observation is not yet known.
dc.description18
dc.description7
dc.description1038
dc.description1041
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionFAPESP [2010/10725-4]
dc.languageen
dc.publisherSage Publications Ltd
dc.publisherLondon
dc.publisherInglaterra
dc.relationMultiple Sclerosis Journal
dc.relationMult. Scler. J.
dc.rightsfechado
dc.rightshttp://www.uk.sagepub.com/aboutus/openaccess.htm
dc.sourceWeb of Science
dc.subjectcerebrospinal fluid
dc.subjectmultiple sclerosis
dc.subjectnatalizumab therapy
dc.subjectoligoclonal bands
dc.subjectResponses
dc.titleDisappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución